Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV cohort study (SHCS)

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 4, 2013, Pages 396-404

  Nüesch, Reto ^a   Wang, Qing ^b   Elzi, Luigia ^c   Bernasconi, Enos ^d   Weber, Rainer ^e   Cavassini, Matthias ^f   Vernazza, Pietro ^g   Thurnheer, Maria C ^h   Calmy, Alexandra ⁱ   Battegay, Manuel ^a   Bucher, Heiner C ^b,c  

^a Klinik St Anna   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antiretroviral therapy; Cardiovascular event; HIV infection; Hypertension; Risk factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY; VIRUS LOAD; WAIST HIP RATIO;

ADULT; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SWITZERLAND;

EID: 84876400269     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182847cd0     Document Type: Article

References (66)

1. Collaboration ATC. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
2. d'Arminio Monforte A, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005;165:416-423.
3. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95.
4. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
5. Manner IW, Baekken M, Oektedalen O, et al. Effect of HIV duration on ambulatory blood pressure in HIV-infected individuals with high office blood pressure. Blood Press. 2010;19:188-195.
6. Vance DE, Mugavero M, Willig J, et al. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care. 2011;22:17-25.
7. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100-109.
8. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-1608.
9. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med. 1996;2:1371-1375.
10. Baker JV, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis. 2011;53:826-835.
11. Bragardo M, Buonfiglio D, Feito MJ, et al. Modulation of lymphocyte interaction with endothelium and homing by HIV-1 gp120. J Immunol. 1997;159:1619-1627.
12. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929-939.
13. Canque B, Marandin A, Rosenzwajg M, et al. Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV). Virology. 1995;208:779-783.
14. Charakida M, Loukogeorgakis SP, Okorie MI, et al. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. Antivir Ther. 2009;14:1075-1079.
15. Cornali E, Zietz C, Benelli R, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol. 1996;149:1851-1869.
16. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
17. Gujuluva C, Burns AR, Pushkarsky T, et al. HIV-1 penetrates coronary artery endothelial cells by transcytosis. Mol Med. 2001;7:169-176.
18. Ho JE, Scherzer R, Hecht FM, et al. The association of CD4+ T-cell count on cardiovascular risk in treated HIV disease. AIDS. 2012;26:1115-1120.
19. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011;217:207-213.
20. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
21. Lafon ME, Steffan AM, Royer C, et al. HIV-1 infection induces functional alterations in human liver endothelial cells in primary culture. AIDS. 1994;8:747-752.
22. Nakamuta S, Endo H, Higashi Y, et al. Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells. J Neurovirol. 2008;14: 186-195.
23. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185: 456-462.
24. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
25. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
26. Baekken M, Os I, Sandvik L, et al. Hypertension in an urban HIVpositive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126-2133.
27. Crane HM, Grunfeld C, Harrington RD, et al. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med. 2009;10:496-503.
28. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019-1026.
29. Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther. 2010;15:363-375.
30. Peyriere H, Eiden C, Macia JC, et al. Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother. 2012;46:703-709.
31. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7:404-410.
32. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2009;39:1179-1189.
33. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;25: 1751-1762.
34. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25: 1105-1187.
35. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18:308-347.
36. Chuang-Stein C, Tong DM. The impact and implication of regression to the mean on the design and analysis of medical investigations. Stat Methods Med Res. 1997;6:115-128.
37. Armah K, Justice A, Oursler K, et al. The impact of elevated and prehypertensive systolic blood pressure and the risk of acute myocardial infarction in HIV+ and HIV- veterans. Paper presented at: 19th Conference on Retroviruses and Oppotunistic Infections CROI, March 5-8, 2012; Seattle, Washington, DC.
38. Chow F, Regan S, Foske S, et al. HIV is an independent risk factor for ischemic stroke: US health care system. Paper presented at: 19th Conference on Retroviruses and Oppotunistic Infections CROI, March 5-8, 2012; Seattle, Washington, DC.
39. Monroe AK, Chander G, Moore RD. Control of medical comorbidities in individuals with HIV. J Acquir Immune Defic Syndr. 2011;58:458-462.
40. Franklin SS, Wt Gustin, Wong ND, et al. Hemodynamic patterns of agerelated changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308-315.
41. Marques-Vidal P, Paccaud F. Regional differences in self-reported screening, prevalence and management of cardiovascular risk factors in Switzerland. BMC Public Health. 2012;12:246.
42. Guessous I, Bochud M, Theler JM, et al. 1999-2009 trends in prevalence, unawareness, treatment and control of hypertension in Geneva, Switzerland. PLoS One. 2012;7:e39877.
43. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;CD005182.
44. Spranger CB, Ries AJ, Berge CA, et al. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med. 2004;117:14-18.
45. Yokokawa H, Goto A, Sanada H, et al. Achievement status toward goal blood pressure levels and healthy lifestyles among Japanese hypertensive patients; cross-sectional survey results from Fukushima Research of Hypertension (FRESH). Intern Med. 2011;50:1149-1156.
46. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290:199-206.
47. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303: 2043-2050.
48. Estoppey D, Paccaud F, Vollenweider P, et al. Trends in self-reported prevalence and management of hypertension, hypercholesterolemia and diabetes in Swiss adults, 1997-2007. BMC Public Health. 2011;11:114.
49. Andersen UO, Jensen GB. Trends and determinant factors in hypertension control in a population study with 25 years of follow-up. J Hypertens. 2010;28:1091-1096.
50. Nilsson PM, Cederholm J, Zethelius BR, et al. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20:348-354.
51. McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011;183:1007-1013.
52. Gu D, Reynolds K, Wu X, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension. 2002;40:920-927.
53. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327: 543-547.
54. Laverty AA, Bottle A, Majeed A, et al. Blood pressure monitoring and control by cardiovascular disease status in UK primary care: 10 year retrospective cohort study 1998-2007. J Public Health (Oxf). 2011;33:302-309.
55. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
56. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25:484-491.
57. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med. 2001;161:1183-1192.
58. Sabin CA, d'Arminio Monforte A, Friis-Moller N, et al. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008;46:1101-1110.
59. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
60. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009;201:318-330.
61. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24:2131- 2141.
62. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
63. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-1574.
64. Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep. 2006;8:403-408.
65. Vecchiet J, Ucciferri C, Falasca K, et al. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther. 2011;16:639-645.
66. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307:1273-1283.